Literature DB >> 22239731

Couples' reasons for adherence to, or discontinuation of, PDE type 5 inhibitors for men with erectile dysfunction at 12 to 24-month follow-up after a 6-month free trial.

Helen M Conaglen1, John V Conaglen.   

Abstract

INTRODUCTION: The history of treatments for erectile dysfunction (ED) has involved a repeated pattern of uptake, followed by abandonment of the various therapies in the medium term. Even effective and simple to use medications are not necessarily continued; discontinuation rates range between 15% and 60%. Despite the association between partner sexual function and men's use of PDE5, no previous studies have reported any contact with partners of men taking PDE5 for their ED. This study involved both partners in couples followed up at least 1 year after treatment of ED. AIM: The study sought clarification of factors influencing adherence to, or discontinuation of, oral ED medications from couples. We hypothesized that many factors contribute to decision making about ED medication use at >12 months. MAIN OUTCOME MEASURES: The main outcome measures of this article were interviews and International Index of Erectile Function-erectile function domain.
METHODS: A total of 155 interviews were conducted seeking details of frequency of usage and preference for the drugs available; reasons for that choice, or for discontinuation of use, were also sought.
RESULTS: Of men interviewed, 71% were using PDE5 at 18 months. Most men interviewed were using the oral medications either 1-2x/week or 1-2x/month. Forty-four percent of men who had decreased their use of the medications reported less need for them. Thirty-four men said the main reason they were using less medication was cost. "Partner issues" from the men's perspective were seldom reported in this study. However, for a number of women, "partner issues" meant a range of problems from separation to alcohol abuse, lack of communication, and lack of confidence, or fear of failure.
CONCLUSIONS: This is the first study to ask couples why they decided to continue or stop using PDE5 when followed up. Female partners provided a different perspective on "partner issues" often cited as reasons for discontinuing PDE5 use. It was also clear that discontinuation did not mean couples were no longer sexually active.
© 2012 International Society for Sexual Medicine.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22239731     DOI: 10.1111/j.1743-6109.2011.02625.x

Source DB:  PubMed          Journal:  J Sex Med        ISSN: 1743-6095            Impact factor:   3.802


  10 in total

1.  Sexual medicine: Why stop a good thing? Discontinuing PDE5 inhibitors.

Authors:  Helen M Conaglen; John V Conaglen
Journal:  Nat Rev Urol       Date:  2012-08-14       Impact factor: 14.432

Review 2.  Eroticization as a factor influencing erectile dysfunction treatment effectiveness.

Authors:  K C Kukula; R A Jackowich; R J Wassersug
Journal:  Int J Impot Res       Date:  2013-07-04       Impact factor: 2.896

3.  AUTHOR REPLY: The nuances of GRADE.

Authors:  Trustin Domes; Borna Tadayon Najafabadi; Matthew Roberts; Jeffrey Campbell; Ryan Flannigan; Phil Bach; Premal Patel; Gavin Langille; Yonah Krakowsky; Philippe D Violette
Journal:  Can Urol Assoc J       Date:  2021-12       Impact factor: 1.862

Review 4.  The role of the sexual partner in managing erectile dysfunction.

Authors:  Hongjun Li; Tiejun Gao; Run Wang
Journal:  Nat Rev Urol       Date:  2016-02-02       Impact factor: 14.432

Review 5.  Men's beliefs about treatment for erectile dysfunction-what influences treatment use? A systematic review.

Authors:  Paul Williams; Hayley McBain; Aliya Amirova; Stanton Newman; Kathleen Mulligan
Journal:  Int J Impot Res       Date:  2020-03-31       Impact factor: 2.896

6.  Adherence to phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction in long-term users: how do men use the inhibitors?

Authors:  Ana Carvalheira; Vera Forjaz; Nuno Monteiro Pereira
Journal:  Sex Med       Date:  2014-06       Impact factor: 2.491

Review 7.  A Psychosocial Approach to Erectile Dysfunction: Position Statements from the European Society of Sexual Medicine (ESSM).

Authors:  Marieke Dewitte; Carlo Bettocchi; Joanna Carvalho; Giovanni Corona; Ida Flink; Erika Limoncin; Patricia Pascoal; Yacov Reisman; Jacques Van Lankveld
Journal:  Sex Med       Date:  2021-10-07       Impact factor: 2.491

8.  Reasons and predictive factors for discontinuation of PDE-5 inhibitors despite successful intercourse in erectile dysfunction patients.

Authors:  S-C Kim; Y-S Lee; K-K Seo; G-W Jung; T-H Kim
Journal:  Int J Impot Res       Date:  2013-12-05       Impact factor: 2.896

9.  Sexual dysfunction and infertility as late effects of cancer treatment.

Authors:  Leslie R Schover; Marleen van der Kaaij; Eleonora van Dorst; Carien Creutzberg; Eric Huyghe; Cecilie E Kiserud
Journal:  EJC Suppl       Date:  2014-05-29

10.  Expectations do not Influence the Response to Phosphosdiesterase Type 5 Inhibitor Therapy for Erectile Dysfunction.

Authors:  Connie C J Louizos; Peter K Knight
Journal:  Pharmacy (Basel)       Date:  2015-11-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.